This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Andersson KE (2000a) New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms. BJU Int 86(S2): 36–43
Andersson KE (2000b) Treatment of overactive bladder: other drug mechanisms. Urology 55 (5A Suppl): 51–57; discussion 59
Araki I (1994) Inhibitory postsynaptic currents and the effects of GABA on visually identified sacral parasympathetic preganglionic neurons in neonatal rats. J Neurophysiol 72(6): 2903–2910
Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12(4): 1693–1703
Chancellor MB, de Groat WC (1999) Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162(1): 3–11
Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38(1): 2–19
de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50 (6A Suppl): 36–52; discussion 53–56
de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Ann Rev Pharmacol Toxicol 41: 691–721
Dmochowski RR, Appell RA (2000) Advancements in pharmacologic management of the overactive bladder. Urology 56 (6 Suppl 1): 41–49
Doren M (1998) Urogenital aging-creation of improved awareness. Am J Obstet Gynecol 178(5): S254–S256
Downie JW (1999) Pharmacological manipulation of central micturition circuitry. Curr Opin Investig Drugs 1: 231–239
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139(5): 919–922
Harriss DR, Marsh KA, Birmingham AT, Hill SJ (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154(3): 1241–1245
Hegde SS, Choppin A, Bonhaus D et al. (1997) Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120 (8): 1409–1418
Hills CJ, Winter SA, Balfour JA (1998) Tolterodine. Drugs 55(6): 813–820; discussion 821–822
Hjalmas K (1999) Desmopressin treatment: current status. Scand J Urol Nephrol Suppl 202: 70–72
Kakizaki H, Yoshiyama M, de Groat WC (1996) Role of NMDA and AMPA glutamatergic transmission in spinal c-fos expression after urinary tract irritation. Am J Physiol 270(5 Pt 2): R990–996
Kay G, Crook T, Rekeda L et al. (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50(2): 317–26
Kenny BA, Miller AM, Williamson IJ, J OC, Chalmers DH, Naylor AM (1996) Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 118(4): 871–878
Kuiper GG, Gustafsson JA (1997) The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410(1): 87–90
Ozawa H, Chancellor MB, Jung SY, et al. (1999) Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 162(6): 2211–2216
Pakulski C, Drobnik L, Millo B (2000) Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 6(2): 314–8
Parczyk K, Schneider MR (1996) The future of antihormone therapy: innovations based on an established principle. J Cancer Res Clin Oncol 122(7): 383–396
Pitsikas N (2000) Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs 1(1): 116–121
Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3): 413–492
Robertson G, Rittig S, Kovacs L, Gaskill MB, Zee P, Nanninga J (1999) Pathophysiology and treatment of enuresis in adults. Scand J Urol Nephrol Suppl 202: 36–38; discussion 38–39
Robinson D, Cardozo L, Terpstra G, Bolodeoku J (2007) A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100(4): 840–5
Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155(3): 1023–1029
Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164(3 Pt 1): 692–697
Schwinn DA (2001) The role of alpha-1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 88 (Suppl 2): 27–34; discussion 49–50
Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE (2001) Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 20: 105–113
Somogyi GT, Tanowitz M, Zernova G, de Groat WC (1996) M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol 496 (Pt 1): 245–254
Steers WD, Herschorn S, Kreder KJ, et al. (2007) Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 100(2): 337–45
Testa R, Guarneri L, Poggesi E, et al. (1999) Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: comparison with WAY 100635. J Pharmacol Exp Ther 290(3): 1258–1269
Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274(2): 1014–24
Truss MC, Stief CG, Uckert S et al. (2000) Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18 (6): 439–443
Truss MC, Stief CG, Uckert S et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19(5): 344–350
Wheeler MA, Smith SD, Saito N, Foster HE jr, Weiss RM (1997) Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. J Urol 158(6): 2045–2050
Yokoyama O, Yoshiyama M, Namiki M, de Groat WC (2000) Role of the forebrain in bladder overactivity following cerebral infarction in the rat. Exp Neurol 163(2): 469–476
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hampel, C., Thüroff, J. (2012). Pharmakologie des Harntraktes. In: Schultz-Lampel, D., Goepel, M., Haferkamp, A. (eds) Urodynamik. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13016-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-13016-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13015-1
Online ISBN: 978-3-642-13016-8
eBook Packages: Medicine (German Language)